Guidelines and Standards
Australian
- Factor VIII and Factor IX Guidelines
(1.3MB)
These evidence-based clinical guidelines detail treatment regimens and alternatives for people with haemophilia A and B, and von Willebrand disease. These guidelines are intended to inform clinicians and people with haemophilia of the safest and most effective strategies using the best available evidence.
In addition to reflecting recent changes to national policy and the availability of recombinant factors, they provide detailed guidance on the selection and use of appropriate products for prophylaxis, treatment of acute bleeding episodes, surgical and dental procedures, antenatal care and delivery of infants. They also provide strategies for using adjunctive agents, managing inhibitors, and address the lack of consensus surrounding tolerization protocols.
- Warfarin Reversal Guidelines
- Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics - June 2003 (850KB)
This document, produced by the National Blood Authority and approved by the National Health and Medical Research Council, updates previous guidelines on the use of Rh D immunoglobulin (anti-D) released in 1999. It aims to inform clinicians, other health professionals and policy makers about the revised recommendations for use of anti-D in Australia.
Since the release of this document, the National Blood Authority has announced Stage 2 in a three-stage program, which extends routine antenatal prophylaxis to all Rh (D) negative women without preformed antibodies.
International
- British Committee for Standards in Haematology (BH)
This web site provides access to BH guidelines and information on work in progress. A facility to register for email alerts to final drafts of guidelines is also provided.
- UK Blood Service
This site provides information on safe and appropriate use of blood including clinical guidelines, clinical audits and publications.
Other Resources
